Technical Analysis for SRPT - Sarepta Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Resistance | Bearish | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| Multiple of Ten Bearish | Other | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Fell Below 50 DMA | Bearish | -0.57% | |
| Calm After Storm | Range Contraction | -0.57% | |
| Narrow Range Bar | Range Contraction | -0.57% | |
| Multiple of Ten Bearish | Other | -0.57% | |
| Wide Bands | Range Expansion | -0.57% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Down 2 % | about 10 hours ago |
| Down 1% | about 10 hours ago |
| 60 Minute Opening Range Breakdown | about 11 hours ago |
| Fell Below Previous Day's Low | about 13 hours ago |
| 50 DMA Resistance | about 14 hours ago |
Get a Trading Assistant
- Earnings date: 05/02/2023
Sarepta Therapeutics, Inc. Description
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Its lead product candidate is eteplirsen, an antisense PMO-based therapeutic, which is in Phase IIb clinical development for the treatment of individuals with Duchenne muscular dystrophy. The company is also involved in developing treatments that are in Phase I clinical trials for infectious diseases, including AVI-7288 for Marburg virus; and AVI-7100 for H1N1 influenza virus. In addition, it focuses on developing preclinical research product candidates for the treatment of other neuromuscular, infectious, and rare diseases. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Biology Infectious Diseases Clinical Development Rare Diseases Clinical Research Influenza Dystrophy Muscular Dystrophy Duchenne Muscular Dystrophy Duchenne Therapeutic Gene Modulation Antisense RNA Sarepta Therapeutics
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 159.835 |
| 52 Week Low | 61.28 |
| Average Volume | 1,432,101 |
| 200-Day Moving Average | 110.92 |
| 50-Day Moving Average | 130.13 |
| 20-Day Moving Average | 140.00 |
| 10-Day Moving Average | 136.95 |
| Average True Range | 7.42 |
| RSI | 44.13 |
| ADX | 22.84 |
| +DI | 27.05 |
| -DI | 33.56 |
| Chandelier Exit (Long, 3 ATRs) | 137.57 |
| Chandelier Exit (Short, 3 ATRs) | 139.38 |
| Upper Bollinger Bands | 165.08 |
| Lower Bollinger Band | 114.93 |
| Percent B (%b) | 0.27 |
| BandWidth | 35.82 |
| MACD Line | 0.38 |
| MACD Signal Line | 3.17 |
| MACD Histogram | -2.7974 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 136.56 | ||||
| Resistance 3 (R3) | 136.56 | 133.84 | 135.19 | ||
| Resistance 2 (R2) | 133.84 | 131.76 | 133.84 | 134.74 | |
| Resistance 1 (R1) | 131.11 | 130.47 | 129.75 | 131.11 | 134.28 |
| Pivot Point | 128.39 | 128.39 | 127.71 | 128.39 | 128.39 |
| Support 1 (S1) | 125.66 | 126.31 | 124.30 | 125.66 | 122.48 |
| Support 2 (S2) | 122.94 | 125.02 | 122.94 | 122.02 | |
| Support 3 (S3) | 120.21 | 122.94 | 121.57 | ||
| Support 4 (S4) | 120.21 |
